A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

NCT05728489 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: BI 765250
DRUG: Placebo

Sponsor

Boehringer Ingelheim